Clinical Trials Browser

Graft vs Host Disease × thymoglobulin × Myeloid × Clear all

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, B-Cell, Hematologic Neoplasms

NCT01471444 2021-12-16

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 3 Completed

256 enrolled 13 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00813124 2021-02-11

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Phase 2 Completed

24 enrolled 8 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00822770 2020-10-14

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Phase 1/2 Completed

47 enrolled 8 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00506948 2020-09-24

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Phase 2 Terminated

13 enrolled 5 charts

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02877082 2018-04-30

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Phase 2 Terminated

5 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT01390402 2016-02-03

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Phase 2 Completed

6 enrolled 3 charts

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00720629 2014-07-18

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 2 Terminated

8 enrolled 11 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

Clinical Trials

HLA

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation